efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease
Published 8 months ago • 842 plays • Length 35:40Download video MP4
Download video MP3
Similar videos
-
54:16
effects of canagliflozin versus finerenone on cardiorenal outcomes
-
49:46
target bp in ckd patients in the post-sprint era
-
3:20
expert in interview: alberto ortiz, editor in chief of clinical kidney journal (ckj)
-
9:06
sglt2 inhibitors in chronic kidney disease
-
1:06:58
e-seminar #1 new pharmacological therapies to slow the progression of diabetic kidney disease
-
1:02:19
optimizing the care and outcomes of patients with ckd: the role of the nephrologist
-
6:11
dapa-ckd: does confirmed renoprotection make the case for first-line sglt2 inhibition? | luigi gnudi
-
56:43
renal events in patients receiving neprilysin inhibitors: a systematic review and meta-analysis
-
47:50
non-alcoholic fatty liver disease and chronic kidney disease: what is the link
-
57:22
emerging data from empa-kidney study
-
54:06
social determinants of health, the transition from advanced chronic kidney disease to kidney failure
-
57:17
how to optimize the nutritional care in patients with ckd?
-
0:55
trailer protein energy wasting in ckd
-
21:02
part 5 - anaemia management in ckd - dr amit gupta, lucknow
-
1:04:16
new pharmacological therapies to slow the progression of diabetic kidney disease e-seminar #4
-
1:50
opening press conference of the 54th era-edta congress
-
41:59
the association between dual raas inhibition and risk of aki and hyperkalemia in patients with dkd